Fig. 1 · Structure

Documents & Downloads

Dexmedetomidine HCl

Cat. No. A11846 CAS 145108-58-3

alpha2-adrenoceptor agonist

Dexmedetomidine hydrochloride is the active isomer of medetomide which acts a potent, highly selective alpha2-AR (alpha2-adrenoceptor) agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
alpha-2 adrenoceptor

Dexmedetomidine HCl Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Dexmedetomidine HCl from 3 published references. In vitro models include NR8383 alveolar macrophages. In vivo models include dechorionated larvae at 48 h post-fertilization (hpf).

Dexmedetomidine HCl In Vitro Studies

Dexmedetomidine was evaluated in LPS-treated NR8383 alveolar macrophages against LPS-incubated cells. Viability reached its highest value of 77.2 ± 7.244% at 10μmol/L DEX. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Viability of LPS-Treated Alveolar Macrophages

Cell-based study · NR8383 alveolar macrophages [1]

LPS-treated NR8383 alveolar macrophages were pre-incubated with Dexmedetomidine, with LPS-incubated cells serving as the comparison. Viability reached its highest value of 77.2 ± 7.244% at 10μmol/L DEX.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viability of LPS-treated NR8383 cellscell viability 77.2 ± 7.244%[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.01, 0.1, 1, 10, or 50 μmol/L
Exposure duration
LPS for 24h; DEX for 2h
Method
pre-incubated
Co-treatment
Other interventions in this design: LPS 10μg/ml. Compound effect isolated by the comparison: LPS-incubated cells.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Dexmedetomidine

The paper names Dexmedetomidine without stating the salt or form; not verified as the hydrochloride form supplied as A11846. No dose conversion or lot validation.

Materials and methods > Animals preparation and experimental protocols (S6, S8, S9); Materials and methods > Cell viability (S27); Results > Using HO-1siRNA NR8383 cells to validate DEX mitigated LPS-induced oxidative injury by preserving mitochondrial dynamics through the HIF-1a/HO-1 pathway (S182, S183, S184, S191)

viability of LPS-treated NR8383 cells: viability of LPS-treated NR8383 cells; comparator: LPS-incubated cells — Results > Using HO-1siRNA NR8383 cells to validate DEX mitigated LPS-induced oxidative injury by preserving mitochondrial dynamics through the HIF-1a/HO-1 pathway (S182, S184)

Dexmedetomidine HCl In Vivo Studies

Dechorionated larvae treated with Dexmedetomidine HCl at 250 µM showed 100% survival without observable developmental defects during observation. Exposure to Dexmedetomidine HCl at 500 µM produced a 40% mortality rate by 48 hpt. In mice, Dexmedetomidine injections at 100 μg/kg induced endogenous cfos expression widely in the examined area relative to saline injection. [2,3]

Larval Survival During Exposure

Animal study · dechorionated larvae at 48 h post-fertilization (hpf) [2]

Dechorionated larvae at 48 h post-fertilization were exposed to 250 µM Dexmedetomidine HCl in E3 embryo medium. Treatment resulted in 100% survival, with no observable developmental defects throughout the observation period.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survivalsurvival 100% survival[2]

Conditions shared by the study groups

Route
in E3 embryo medium
Treatment course
48 h of DEX exposure
Vehicle
E3 embryo medium
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dexmedetomidine HCl 250 µMUntreated larvaeTreatment with 250 µM DEX resulted in 100% survival, with no observable developmental defects throughout the 48-h observation period[2]
Dexmedetomidine HCl 250 µM
Model: dechorionated larvae at 48 h post-fertilization (hpf)
Methods and source locations

Compound reported in the paper: Dexmedetomidine HCl; Compound label in the paper: Dexmedetomidine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Toxicity Assay (S5, S7, S8, S12); Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S103, S104); Fig. 1 legend (S190)

survival: survival; comparator: Untreated larvae — Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S103, S104)

Dexmedetomidine HCl 250 µM · Materials and Methods > Toxicity Assay (S8, S12); Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S104)

Endogenous cFOS expression in mice

Animal study · Mice [3]

Mice received Dexmedetomidine injections at 100 μg/kg. Endogenous cfos expression was induced widely in the examined area relative to expression after saline injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
endogenous cFOS expressionReported result 30 or 60 minutes after dexmedetomidine (100 μg/kg) injections: relative to its expression after a saline injection, the endogenous cfos gene is induced widely in the area by sedative doses of dexmedetomidine.[3]

Conditions shared by the study groups

Route
injected
Treatment course
30 or 60 minutes afterwards
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dexmedetomidine 100 μg/kgcontrol saline30 or 60 minutes after dexmedetomidine (100 μg/kg) injections: relative to its expression after a saline injection, the endogenous cfos gene is induced widely in the area by sedative doses of dexmedetomidine.[3]
Dexmedetomidine 100 μg/kg
Model: Mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Dexmedetomidine

The paper names Dexmedetomidine without stating the salt or form; not verified as the hydrochloride form supplied as A11846. No dose conversion or lot validation.

RESULTS > TetTagging neurons in the preoptic hypothalamus (S26, S27); Figure 2 legend (S234)

endogenous cFOS expression: endogenous cFOS expression; comparator: control saline — RESULTS > TetTagging neurons in the preoptic hypothalamus (S27); Figure 2 legend (S234)

Dexmedetomidine 100 μg/kg · RESULTS > TetTagging neurons in the preoptic hypothalamus (S26, S27); Figure 2 legend (S234)

Mortality in dechorionated larvae

Animal study · dechorionated larvae at 48 h post-fertilization (hpf) [2]

Dechorionated larvae exposed to Dexmedetomidine HCl at 500 µM in E3 embryo medium showed a 40% mortality rate by 48 hpt.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mortality ratemortality rate 40% mortality rate[2]

Conditions shared by the study groups

Route
in E3 embryo medium
Treatment course
48 h of DEX exposure
Vehicle
E3 embryo medium
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dexmedetomidine HCl 500 µMUntreated larvae500 µM DEX: a 40% mortality rate by 48 hpt.[2]
Dexmedetomidine HCl 500 µM
Model: dechorionated larvae at 48 h post-fertilization (hpf)
Methods and source locations

Compound reported in the paper: Dexmedetomidine HCl; Compound label in the paper: Dexmedetomidine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Toxicity Assay (S5, S7, S8, S12); Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S105); Fig. 1 legend (S190)

mortality rate: mortality rate; comparator: Untreated larvae — Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S105)

Dexmedetomidine HCl 500 µM · Materials and Methods > Toxicity Assay (S8, S12); Results > Effects of DEX Exposure on Survival and Morphology in Zebrafish Larvae (S105)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 145108-58-3
Applications alpha2-adrenoceptor agonist
Formula C13H16N2.HCl
Molecular Weight 236.74
Synonyms d-Medetomidine hydrochloride
SMILES
CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 43 mg/mL (181.63 mM)
Water Insoluble
Ethanol 43 mg/mL (181.63 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dexmedetomidine HCl Research References

  1. [1] Shi J, Yu T, Song K, et al. Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway. Redox Biol (2021). PMID: 33774474 DOI: 10.1016/j.redox.2021.101954 Source material
  2. [2] Nazli D, Poyraz YK, Can K, et al. Dexmedetomidine Exerts Multi-level Effects to Ameliorate Alzheimer's Disease Pathology in the Adult Zebrafish Brain. Mol Neurobiol (2026). PMID: 42082800 DOI: 10.1007/s12035-026-05906-9 Source material
  3. [3] Zhang Z, Ferretti V, Güntan İ, et al. Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists. Nat Neurosci (2015). PMID: 25706476 DOI: 10.1038/nn.3957 Source material

Added to your cart

View Cart Checkout
Loading...